参考文献/References:
[1] Davie CA. A review of Parkinson's disease[J]. Br Med Bull, 2008, 86(4): 109-127.
[2] Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment[J]. J Neurol Neurosurg Psychiatry, 2020, 91(8): 795-808.
[3] Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: a review[J]. JAMA, 2020, 323(6): 548-560.
[4] Choong CJ, Mochizuki H. Neuropathology of alpha-synuclein in Parkinson's disease[J]. Neuropathology, 2022, 42(2): 93-103.
[5] Burré J, Sharma M, Südhof TC. Cell biology and pathophysiology of α-Synuclein[J]. Cold Spring Harb Perspect Med, 2018, 8(3): a024091.
[6] Singh PK, Muqit M. Parkinson's: A disease of aberrant vesicle trafficking[J]. Annu Rev Cell Dev Biol, 2020, 36(8): 237-264.
[7] Lautenschläger J, Stephens AD, Fusco G, et al. C-terminal Calcium binding of α-synuclein modulates synaptic vesicle interaction[J]. Nat Commun, 2018, 9(1): 712.
[8] Lashuel HA, Overk CR, Oueslati A, et al. The many faces of α-synuclein: from structure and toxicity to therapeutic target[J]. Nat Rev Neurosci, 2013, 14(1): 38-48.
[9] Segura-Aguilar J, Paris I, Muñoz P, et al. Protective and toxic roles of dopamine in Parkinson's disease[J]. J Neurochem, 2014, 129(6): 898-915.
[10] Gallardo MJ, Delgado F. Animal prion diseases: A review of intraspecies transmission[J]. Open Vet J, 2021, 11(4): 707-723.
[11] Sanders DW, Kaufman SK, Holmes BB, et al. Prions and protein assemblies that convey biological information in health and disease[J]. Neuron, 2016, 89(3): 433-448.
[12] Jy L, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation[J]. Nat Med, 2008, 14(5): 501-503.
[13] Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein[J]. Proc Natl Acad Sci USA, 2009, 106(31): 13010-13015.
[14] Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Prion-like spreading of pathological α-synuclein in brain[J]. Brain, 2013, 136(Pt 4): 1128-1138.
[15] Spagnolli G, Requena JR, Biasini E. Understanding prion structure and conversion[J]. Prog Mol Biol Transl Sci, 2020, 175(9): 19-30.
[16] Dearmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases[J]. Am J Pathol, 1995, 146(4): 785-811.
[17] Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases[J]. Nature, 2016, 539(7628): 217-226.
[18] Narkiewicz J, Giachin G, Legname G. In vitro aggregation assays for the characterization of α-synuclein prion-like properties[J]. Prion, 2014, 8(1): 19-32.
[19] Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death[J]. Neuron, 2011, 72(1): 57-71.
[20] Hashimoto M, Hsu LJ, Sisk A, et al. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease[J]. Brain Res, 1998, 799(2): 301-306.
[21] Hasegawa M, Nonaka T, Masuda-Suzukake M. Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders[J]. Pharmacol Ther, 2017, 172(12): 22-33.
[22] Peelaerts W, Bousset L, Van DA, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration[J]. Nature, 2015, 522(7556): 340-344.
[23] Braak H, Del Tredici K. Potential pathways of abnormal Tau and α-Synuclein dissemination in sporadic alzheimer's and parkinson's diseases[J]. Cold Spring Harb Perspect Biol, 2016, 8(11): a023630.
[24] Tarutani A, Suzuki G, Shimozawa A, et al. The effect of fragmented pathogenic α-Synuclein seeds on prion-like propagation[J]. J Biol Chem, 2016, 291(36): 18675-18688.
[25] Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease[J]. Neurobiol Aging, 2002, 24(2): 197-211.
[26] Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease[J]. Nat Med, 2008, 14(5): 504-506.
[27] Recasens A, Ulusoy A, Kahle PJ, et al. In vivo models of alpha-synuclein transmission and propagation[J]. Cell Tissue Res, 2018, 373(1): 183-193.
[28] Dehay B, Fernagut PO. Alpha-synuclein-based models of Parkinson's disease[J]. Rev Neurol(Paris), 2016, 172(6/7): 371-378.
[29] Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model[J]. Neurobiol Aging, 2012, 33(9): 2225-2228.
[30] Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys[J]. Ann Neurol, 2014, 75(3): 351-362.
[31] Fernández-Borges N, Eraña H, Venegas V, et al. Animal models for prion-like diseases[J]. Virus Res, 2015, 207(4): 5-24.
[32] Abounit S, Wu JW, Duff K, et al. Tunneling nanotubes: A possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases[J]. Prion, 2016, 10(5): 344-351.
[33] Abounit S, Bousset L, Loria F, et al. Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes[J]. EMBO J, 2016, 35(19): 2120-2138.
[34] Sherer NM, Mothes W. Cytonemes and tunneling nanotubules in cell-cell communication and viral pathogenesis[J]. Trends Cell Biol, 2008, 18(9): 414-420.
[35] Rostami J, Holmqvist S, Lindström V, et al. Human astrocytes transfer aggregated Alpha-Synuclein via tunneling nanotubes[J]. J Neurosci, 2017, 37(49): 11835-11853.
[36] Bukoreshtliev NV, Wang X, Hodneland E, et al. Selective block of tunneling nanotube(TNT)formation inhibits intercellular organelle transfer between PC12 cells[J]. FEBS Lett, 2009, 583(9): 1481-1488.
[37] Manfredsson FP, Luk KC, Benskey MJ, et al. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human Primate results in gastrointestinal dysmotility and transient CNS pathology[J]. Neurobiol Dis, 2018, 112(1): 106-118.
[38] Uemura N, Yagi H, Uemura MT, et al. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve[J]. Mol Neurodegener, 2018, 13(1): 21.
[39] Tysnes OB, Kenborg L, Herlofson K, et al. Does vagotomy reduce the risk of Parkinson's disease?[J]. Ann Neurol, 2015, 78(6): 1011-1012.
[40] Svensson E, Horvath-Puho E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson's disease[J]. Movement Disorders, 2015, 30(1): S445-S446.
[41] Beekes M. The neural Gut-Brain axis of pathological protein aggregation in parkinson's disease and its counterpart in peroral prion infections[J]. Viruses, 2021, 13(7): 1394.
[42] Svensson E, Horváth-Puhó E, Stokholm MG, et al. Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up[J]. Mov Disord, 2016, 31(12): 1918-1922.
[43] Marras C, Lang EA, Austin PC, et al. Appendectomy in mid and later Life and risk of Parkinson's disease: A population-based study[J]. Mov Disord, 2016, 31(8): 1243-1247.
[44] Killinger B, Madaj Z, Sikora JW, et al. The vermiform appendix impacts the risk of developing Parkinson's disease[J]. Sci Transl Med, 2018, 10(465): eaar5280.
[45] Palacios N, Hughes KC, Cereda E, et al. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women[J]. Mov Disord, 2018, 33(9): 1492-1496.
[46] Goedert M, Falcon B, Clavaguera F, et al. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies[J]. Curr Neurol Neurosci Rep, 2014, 14(11): 495.
[47] Breen DP, Halliday GM, Lang EA. Gut-brain axis and the spread of α-synuclein pathology: Vagal highway or dead end?[J]. Mov Disord, 2019, 34(3): 307-316.
[48] Ayers JI, Brooks MM, Rutherford NJ, et al. Robust central nervous system pathology in transgenic mice following peripheral injection of α-Synuclein fibrils[J]. J Virol, 2017, 91(2): e02016-e02095.
[49] Sacino AN, Brooks M, Thomas MA, et al. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice[J]. Proc Natl Acad Sci U S A, 2014, 111(29): 10732-10737.
[50] Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease[J]. Lancet Neurol, 2019, 18(6): 573-586.
[51] Bousset L, Pieri L, Ruiz-Arlandis G, et al. Structural and functional characterization of two alpha-synuclein strains[J]. Nat Commun, 2013, 4(1): 2575.
[52] Candelise N, Schmitz M, Thüne K, et al. Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays[J]. Transl Neurodegener, 2020, 9(1): 5.